The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.
Voluntary participation in the clinical study; fully informed about the study and signed informed consent, willing to follow and capable of completing all trial procedures[17]
Age: 18 to 75 years old (including the cut-offs)
Subjects must meet at least one of the following criteria for enrollment.
Patients diagnosed with chronic hepatitis B in hospital or out of hospital: persistent positive hepatitis B surface antigen (HBsAg) for 6 months or more
Age <18 years or >75 years
Patients who have been diagnosed with liver cancer before enrollment
Patients with severe mental illness or cognitive impairment
Patients who are pregnant or lactating, or preparing to become pregnant